bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs - PubMed (original) (raw)

. 1992 Oct 1;52(19):5407-11.

Affiliations

PMID: 1394146

bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs

T Miyashita et al. Cancer Res. 1992.

Abstract

The S49.1 and WEHI7.2 murine lymphoid cell lines have been used extensively as models for investigations of programmed cell death ("apoptosis") induced by glucocorticoids such as dexamethasone. Infection of these thymus-derived T-cell lines with a recombinant retrovirus encoding the human M(r) 26,000 Bcl-2 oncoprotein resulted in marked resistance to DEX-mediated cell death and DNA degradation into oligonucleosomal fragments, without interfering with the ability of dexamethasone to suppress cellular proliferation and without lowering levels of glucocorticoid receptors. In contrast, high levels of p26-Bcl-2 production did not block cell killing and DNA fragmentation induced by H2O2, suggesting that the Bcl-2 impairs some but not all pathways for cell death in S49.1 and WEHI7.2 cells that are associated with the DNA fragmentation pattern typical of apoptosis. S49.1 and WEHI7.2 cells infected with bcl-2 but not control retrovirus also exhibited increased resistance to cell killing and DNA fragmentation induced by a wide variety of reagents, including the calcium ionophore ionomycin, the phorbol ester tetradecanoylphorbol acetate, the dihydrofolate reductase inhibitor methotrexate, the antimetabolite 1-beta-D-arabinofuranosylcytosine, and the microtubule inhibitor vincristine. These findings provide evidence that p26-Bcl-2 interferes with a pathway for cell death that is activated by multiple drugs used for the treatment of cancer.

PubMed Disclaimer

Cited by

Exploring the DNA2-PNA heterotriplex formation in targeting the Bcl-2 gene promoter: A structural insight by physico-chemical and microsecond-scale MD investigation.
Falanga AP, Lupia A, Tripodi L, Morgillo CM, Moraca F, Roviello GN, Catalanotti B, Amato J, Pastore L, Cerullo V, D'Errico S, Piccialli G, Oliviero G, Borbone N. Falanga AP, et al. Heliyon. 2024 Jan 22;10(3):e24599. doi: 10.1016/j.heliyon.2024.e24599. eCollection 2024 Feb 15. Heliyon. 2024. PMID: 38317891 Free PMC article.
Updates on Larynx Cancer: Risk Factors and Oncogenesis.
Liberale C, Soloperto D, Marchioni A, Monzani D, Sacchetto L. Liberale C, et al. Int J Mol Sci. 2023 Aug 18;24(16):12913. doi: 10.3390/ijms241612913. Int J Mol Sci. 2023. PMID: 37629093 Free PMC article. Review.
Overcoming apoptotic resistance afforded by Bcl-2 in lymphoid tumor cells: a critical role for dexamethasone.
Bortner CD, Oakley RH, Cidlowski JA. Bortner CD, et al. Cell Death Discov. 2022 Dec 20;8(1):494. doi: 10.1038/s41420-022-01285-x. Cell Death Discov. 2022. PMID: 36539401 Free PMC article.
Potent, p53-independent induction of NOXA sensitizes MLL-rearranged B-cell acute lymphoblastic leukemia cells to venetoclax.
Fidyt K, Pastorczak A, Cyran J, Crump NT, Goral A, Madzio J, Muchowicz A, Poprzeczko M, Domka K, Komorowski L, Winiarska M, Harman JR, Siudakowska K, Graczyk-Jarzynka A, Patkowska E, Lech-Maranda E, Mlynarski W, Golab J, Milne TA, Firczuk M. Fidyt K, et al. Oncogene. 2022 Mar;41(11):1600-1609. doi: 10.1038/s41388-022-02196-y. Epub 2022 Jan 28. Oncogene. 2022. PMID: 35091682 Free PMC article.

bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs - PubMed (original) (raw)